Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 4/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | ULK1 | O75385 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349147 | 1.00 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGAHR | |
| SCHEMBL14702331 | 0.80 | CDK8 (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGRIPK1 | |
| SCHEMBL298532 | 0.78 | CDK8 (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGRIPK1 | |
| SCHEMBL27943918 | 0.78 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGRIPK1 | |
| SCHEMBL30375749 | 0.76 | CYP2A6 (0.53) | AHRPTGS1NQO2 | |
| SCHEMBL31152348 | 0.72 | CDK8 (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGRIPK1 | |
| SCHEMBL299270 | 0.72 | CDK8 (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGRIPK1 | |
| SCHEMBL12459720 | 0.72 | CDK8 (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGRIPK1 | |
| SCHEMBL16026877 | 0.71 | RAB9A (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGRIPK1 | |
| SCHEMBL16026878 | 0.71 | RAB9A (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633750-B1 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | EISAI R&D MAN CO LTD (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-1633750-B1 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | EISAI R&D MAN CO LTD (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20060235042-A1 | Synthesis | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235042-A1 | Synthesis | AZI2, CYP3A5, CYP3A7 | PIK3CD 1329/4885PIK3CA 1933/4885PIK3CB 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.